Alterations in tropomyosin isoform expression in human transitional cell carcinoma of the urinary bladder

International Journal of Cancer

Volumn 110, Issue 3, 2004, Pages 368-373

  Pawlak, Geraldine ^a,d   McGarvey, Terence W ^b   Nguyen, Trang B ^c   Tomaszewski, John E ^b   Puthiyaveettil, Raghunath ^b   Malkowicz, S Bruce ^b,c   Helfman, David M ^a  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d INSTITUT ALBERT BONNIOT   (France)

Author keywords

Bladder neoplasms; Cytoskeleton; Tropomyosin

Indexed keywords

ACTIN BINDING PROTEIN; ISOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; TROPOMYOSIN; TROPOMYOSIN 1; TROPOMYOSIN 2; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CHEMICAL MODIFICATION; CLINICAL PATHWAY; CONTROLLED STUDY; EARLY DIAGNOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; DOWN-REGULATION; ENZYME INHIBITORS; HUMANS; IMMUNOHISTOCHEMISTRY; MAP KINASE SIGNALING SYSTEM; MUCOUS MEMBRANE; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION; TIME FACTORS; TROPOMODULIN; TROPOMYOSIN; UP-REGULATION; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 2442547459     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20151     Document Type: Article

References (27)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Stein JP, Grossfeld GD, Ginsberg DA, Esrig D, Freeman JA, Figueroa AJ, Skinner DG, Cote RJ. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 1998;160:645-59.
3. Burchardt M, Burchardt T, Shabsigh A, De La Taille A, Benson MC, Sawczuk I. Current concepts in biomarker technology for bladder cancers. Clin Chem 2000;46:595-605.
4. Pawlak G, Helfman DM. Cytoskeletal changes in cell transformation and tumorigenesis. Curr Opin Genet Dev 2001;11:41-7.
5. Rao J. Targeting actin remodeling profiles for the detection and management of urothelial cancers-a perspective for bladder cancer research. Front Biosci 2002;7:e1-8.
6. Mialhe A, Louis J, Pasquier D, Rambeaud JJ, Seigneurin D. Expression of three cell adhesion molecules in bladder carcinomas: correlation with pathological features. Anal Cell Pathol 1997;13:125-36.
7. Pittenger MF, Kazzaz JA, Helfman DM. Functional properties of nonmuscle tropomyosin isoforms. Curr Opin Cell Biol 1994;6:96-104.
8. Mahadev K, Raval G, Bharadwaj S, Willingham MC, Lange EM, Vonderhaar B, Salomon D, Prasad GL. Suppression of the transformed phenotype of breast cancer by tropomyosin-1. Exp Cell Res 2002;279:40-51.
9. Prasad GL, Masuelli L, Raj MHG, Harindranath N. Suppression of src-induced transformed phenotype by expression of tropomyosin-1. Oncogene 1999;18:2027-31.
10. Takenaga K, Masuda A. Restoration of microfilament bundle organization in v-raf-transformed NRK cells after transduction with tropomyosin 2 cDNA. Cancer Lett 1994;87:47-53.
11. Gimona M, Kazzaz J, Helfman DM. Forced expression of tropomyosin 2 or 3 in v-Ki-ras-transformed fibroblasts results in distinct phenotypic effects. Proc Natl Acad Sci USA 1996;93:9618-23.
12. Braverman RH, Cooper HL, Lee HS, Prasad GL. Anti-oncogenic effects of tropomyosin: isoform specificity and importance of protein coding sequences. Oncogene 1996;13:537-45.
13. Janssen RAJ, Mier JW. Tropomyosin-2 cDNA lacking the 3′ untranslated region riboregulator induces growth inhibition of v-Ki-ras-transformed fibroblasts. Mol Biol Cell 1997;8:897-908.
14. Franzen B, Linder S, Uryu K, Alaiya AA, Hirano T, Kato H, Auer G. Expression of tropomyosin isoforms in benign and malignant human breast lesions. Brit J Cancer 1996;73:909-13.
15. Wang FL, Wang Y, Wong WK, Liu Y, Addivinola FJ, Liang P, Chen LB, Kantoff PW, Pardee AB. Two differentially expressed genes in normal human prostate tissue and in carcinoma. Cancer Res 1996;56:3634-7.
16. Jung MH, Kim SC, Jeon GA, Kim SH, Kim Y, Choi KS, Park SI, Joe MK, Kimm K. Identification of differentially expressed genes in normal and tumor human gastric tissue. Genomics 2000;69:281-6.
17. Cartun RW, Pedersen CA. An immunocytochemical technique offering increased sensitivity and lowered cost utilizing a streptavidin horseradish peroxidase conjugate. J Histotechnol 1989;12:273-80.
18. Lin JL, Geng X, Bhattacharya SD, Yu JR, Reiter RS, Sastri B, Glazier KD, Mirza ZK, Wang KK, Amenta PS, Das KM, Lin JJ. Isolation and sequencing of a novel tropomyosin isoform preferentially associated with colon cancer. Gastroenterology 2002;123:152-62.
19. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
20. Fujita J, Srivastava SK, Kraus MH, Rhim JS, Tronick SR, Aaronson SA. Frequency of molecular alterations affecting ras protooncogenes in human urinary tract tumors. Proc Natl Acad Sci USA 1985;82:3849-53.
21. Cordon-Cardo S, Sheinfeld J. Molecular and immunopathology studies of oncogenes and tumor-suppressor genes in bladder cancer. World J Urol 1997;15:112-9.
22. Goldfarb M, Shimizu K, Perucho M, Wigler M. Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells. Nature 1982;1:404-9.
23. Pawlak G, Helfman DM. Post-transcriptional down-regulation of ROCKI/Rho-kinase through a MEK-dependent pathway leads to cytoskeleton disruption in ras-transformed fibroblasts. Mol Biol Cell 2002;13:336-47.
24. Ljundahl S, Linger S, Franzen B, Binetruy B, Auer G, Shoshan MC. Down-regulation of tropomyosin-2 expression in c-jun-transformed rat fibroblasts involves induction of a MEK1-dependent autocrine loop. Cell Growth Diff 1998;9:565-73.
25. Sibley K, Cuthbert-Heavens D, Knowles MA. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene 2001;20:686-91.
26. Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Gil Diez de Medina S, Van Rhijn B, Bralet MP, Lefrere-Belda MA, Lahaye JB, Abbou CC, Bonaventure J, Zafrani ES, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001;158:1955-9.
27. Van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001;61:1265-8.